Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'

Go back to Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'

Form 8-K Replimune Group, Inc. For: Jul 21

July 22, 2025 8:19 AM EDT

false 0001737953 0001737953 2025-07-21 2025-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares... More